Skip to content

Clinical trials

Completed Charcot-Marie-Tooth Disease trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Charcot-Marie-Tooth Disease Status: Completed Clear all

50 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20061
20072
20102
20111
20124
20133
20144
20154
20163
20172
20182
20192
20201
20214
20224
20232
20244
20252
20262

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed50

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
University Hospital, Clermont-Ferrand3
University of Iowa3
Ankara City Hospital Bilkent2
Centre Hospitalier Universitaire de Nice2
Istanbul University - Cerrahpasa2
NMD Pharma A/S2
Pharnext S.C.A.2
University College London Hospitals2
University of South Florida2
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Charcot-Marie-Tooth Disease50
Carpal Tunnel Syndrome7
Median Neuropathy4
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating4
Hereditary Sensory and Motor Neuropathy3
Nerve Compression Syndromes3
Neuromuscular Diseases3
Adrenoleukodystrophy2
Amyotrophic Lateral Sclerosis2
Genetic Diseases, Inborn2

Trials

Showing 51 to 50 of 50. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.